| Literature DB >> 27869790 |
James A Cotton1, Sasisekhar Bennuru2, Alexandra Grote3, Bhavana Harsha1, Alan Tracey1, Robin Beech4, Stephen R Doyle1, Matthew Dunn1, Julie C Dunning Hotopp5, Nancy Holroyd1, Taisei Kikuchi1, Olivia Lambert1, Amruta Mhashilkar6, Prudence Mutowo7, Nirvana Nursimulu8,9, Jose M C Ribeiro10, Matthew B Rogers11, Eleanor Stanley1, Lakshmipuram S Swapna9, Isheng J Tsai1, Thomas R Unnasch6, Denis Voronin12, John Parkinson8,9,13, Thomas B Nutman2, Elodie Ghedin3,14, Matthew Berriman1, Sara Lustigman12.
Abstract
Human onchocerciasis is a serious neglected tropical disease caused by the filarial nematode Onchocerca volvulus that can lead to blindness and chronic disability. Control of the disease relies largely on mass administration of a single drug, and the development of new drugs and vaccines depends on a better knowledge of parasite biology. Here, we describe the chromosomes of O. volvulus and its Wolbachia endosymbiont. We provide the highest-quality sequence assembly for any parasitic nematode to date, giving a glimpse into the evolution of filarial parasite chromosomes and proteomes. This resource was used to investigate gene families with key functions that could be potentially exploited as targets for future drugs. Using metabolic reconstruction of the nematode and its endosymbiont, we identified enzymes that are likely to be essential for O. volvulus viability. In addition, we have generated a list of proteins that could be targeted by Federal-Drug-Agency-approved but repurposed drugs, providing starting points for anti-onchocerciasis drug development.Entities:
Mesh:
Year: 2016 PMID: 27869790 PMCID: PMC5310847 DOI: 10.1038/nmicrobiol.2016.216
Source DB: PubMed Journal: Nat Microbiol ISSN: 2058-5276 Impact factor: 17.745
Figure 1O. volvulus chromosomes
a, Lines above the axis show sizes of O. volvulus chromosomes in the assembly and the locations of potential telomeric repeats. Filled circles indicate telomere repeats present in the assembly, open circles are ends of optical map scaffolds (Supplementary Fig. 1c). Rectangular boxes/bars indicate sequence gaps of at least 50 kb. The inferred karyotype for O. volvulus is shown below the axis, based on the assembly and sequence coverage data. b, GC content, gene density and repeat density (proportion of bases in each window covered by genes/at least one annotated repeat) in non-overlapping 10 kb windows for each of the four large scaffolds. Colours and shading indicate scaffold boundaries. c, Comparison of four O. volvulus chromosomes with six C. elegans chromosomes. Links show PROmer hits with similarity greater than 70% over at least 100 amino acids, coloured according to chromosome location of C. elegans hit.
Figure 2Gene family evolution and comparative genomics of O. volvulus and relatives
Maximum-likelihood genome phylogeny of six filarial nematode species and three outgroup species. All nodes were fully supported by 100 bootstrap replicates. The phylogeny is annotated with histograms showing the number of duplications (red) and losses (green) for individual genes (dark red or dark green); number of families (light red or light green) with one or more duplications/losses; and numbers of gene families (light blue) inferred to appear on each branch and (on terminal branches) numbers of singleton genes (dark blue) as estimated by the Ensembl Compara pipeline. Note that our data cannot reconstruct gene losses on the most basal branch of the tree. Bar charts in yellow-red summarize the evolutionary history of the genome of each species, defining genes shared among all nine nematode species, the six filarial species and genes with more complex patterns of conservation. The total heights of these bars represent the total number of protein-coding loci annotated on each genome. Boxes on branches show numbers of gene duplications (+X) and losses (−X) in five gene families of specific interest in O. volvulus: trypsin, cathepsin-L like proteases (CPL), chitinase, serine protease inhibitors (SPI) and prolyl-4 hydroxylase alpha-subunits (P4H) and in other families with many gene duplications on the branch leading to O. volvulus. Duplications are observed in two different Srx GPCR families; the reverse transcriptase gene family could be missing from some species because of differences in annotation and repeat finding methods. Family 4135 comprises weakly conserved hypothetical proteins. Stacked bar charts in blue summarize the genome of each species, with total heights representing the size of each genome assembly, divided into exons, other genic sequences (introns and UTRs; non-coding genes), annotated repeats and DNA sequence not annotated in any of these categories.
Figure 3GPCRs
Profile of GPCR families present in nematode genomes in comparison to O. volvulus. The log of the number of genes plus one is plotted per family.
Overview of the metabolic pathways included in the metabolic reconstructions.
| Number of reactions in pathway
| Number of reactions predicted essential | ||||||
|---|---|---|---|---|---|---|---|
| Superpathway | Metabolic pathway | Ov and | Ov and | ||||
| Amino acid metabolism | Alanine, aspartate and glutamate metabolism | 14 | 15 | 3 | 1 | 1 | 0 |
| Arginine and proline metabolism | 26 | 25 | 2 | 3 | 3 | 0 | |
| Biosynthesis of amino acids | 37 | 41 | 9 | 3 | 3 | 0 | |
| Cysteine and methionine metabolism | 17 | 19 | 2 | 4 | 4 | 0 | |
| Glycine, serine and threonine metabolism | 17 | 17 | 3 | 1 | 1 | 0 | |
| Biosynthesis of other secondary metabolites | Streptomycin biosynthesis | 4 | 4 | 0 | 2 | 2 | 0 |
| Carbohydrate metabolism | Amino sugar and nucleotide sugar metabolism | 23 | 23 | 3 | 4 | 4 | 0 |
| Butanoate metabolism | 8 | 8 | 0 | 1 | 0 | 0 | |
| Inositol phosphate metabolism | 12 | 12 | 0 | 3 | 3 | 0 | |
| Pentose phosphate pathway | 17 | 18 | 0 | 2 | 2 | 0 | |
| Propanoate metabolism | 14 | 14 | 1 | 1 | 1 | 0 | |
| Pyruvate metabolism | 20 | 20 | 1 | 1 | 1 | 0 | |
| Energy metabolism | Methane metabolism | 16 | 16 | 0 | 2 | 2 | 0 |
| Lipid metabolism | Arachidonic acid metabolism | 16 | 14 | 0 | 3 | 3 | 0 |
| Biosynthesis of unsaturated fatty acids | 14 | 15 | 2 | 7 | 2 | 0 | |
| Fatty acid biosynthesis | 3 | 15 | 32 | 1 | 1 | 0 | |
| Fatty acid degradation | 32 | 32 | 0 | 19 | 0 | 0 | |
| Fatty acid elongation | 28 | 28 | 0 | 24 | 0 | 0 | |
| Fatty acid metabolism | 48 | 57 | 32 | 31 | 2 | 0 | |
| Glycerolipid metabolism | 9 | 9 | 0 | 2 | 2 | 0 | |
| Glycerophospholipid metabolism | 22 | 22 | 1 | 6 | 6 | 0 | |
| Sphingolipid metabolism | 16 | 16 | 0 | 5 | 5 | 0 | |
| Metabolism of cofactors and vitamins | Nicotinate and nicotinamide metabolism | 11 | 12 | 1 | 1 | 0 | 1 |
| One carbon pool by folate | 10 | 10 | 6 | 1 | 0 | 0 | |
| Pantothenate and CoA biosynthesis | 11 | 11 | 1 | 3 | 3 | 0 | |
| Metabolism of other amino acids | Beta-alanine metabolism | 9 | 9 | 0 | 1 | 1 | 0 |
| Glutathione metabolism | 19 | 18 | 0 | 2 | 2 | 0 | |
| Metabolism of terpenoids and polyketides | Terpenoid backbone biosynthesis | 12 | 12 | 2 | 8 | 8 | 0 |
| Tetracycline biosynthesis | 1 | 1 | 0 | 1 | 1 | 0 | |
| Nucleotide metabolism | Purine metabolism | 53 | 63 | 9 | 7 | 3 | 0 |
| Pyrimidine metabolism | 47 | 51 | 7 | 7 | 5 | 0 | |
| Transport reactions | Extracellular transport | 43 | 43 | 0 | 23 | 18 | 0 |
| Total (non-redundant) number of reactions in pathways | 428 | 455 | 72 | 86 | 49 | 1 | |
| Total number of reactions in reconstructions | 777 | 796 | 100 | 112 | 70 | 1 | |
One reaction was essential either from L. loa (with or without genetic evidence); O. volvulus (Ov) and Wolbachia (wOv) with reactions in the O. volvulus reconstruction (both from gene annotation and added in pathway gap-filling) not being contributed by wOv only; or wOv with reactions in the Ov reconstruction supported by genetic evidence only from wOv.
Only a single reaction, in the nicotinate and nicotinamide pathway, is essential and uniquely provided by wOv. Transport reactions for both nematode and Wolbachia lack genetic evidence therefore making wOv only and O. volvulus and wOv transporters indistinguishable.
Note that of the 18 transport reactions essential to O. volvulus, all are essential to L. loa as well except for threonine transport. Also reported is the total number of reactions belonging to the pathways listed here, as well as the total number of reactions in the reconstructions.
Figure 4Contribution of Wolbachia to O. volvulus in purine metabolism
Inhibitors 8-amino-5′-deoxy-5′chloroguanosine and (−)-epicatechin (shown in the figure) have been found against the activities of purine nucleoside phosphorylase (EC 2.4.2.1) and ribonucleoside diphosphate reductase (EC 1.17.4.1)[113,114]. The chemical structures of the inhibitors shown were obtained from the Braunschweig Enzyme Database (BRENDA)[115]. Metabolites in bold represent biomass components.
The top 16 O. volvulus targets and their predicted drugs.
| Ov gene ID | Function of family | Drugs (WHO name) | ATC level 3 classification |
|---|---|---|---|
| OVOC2713 | Ribonucleotide reductase, small chain | Fludarabine phosphate, clofarabine, gemcitabine, (hydroxyurea), gallium nitrate | Antimetabolites, other antineoplastic agents. |
| OVOC11146 | Calcineurin-like phosphoesterase | Tiagabine | Antiepileptics |
| OVOC215 | Sodium neurotransmitter symporter family | Imipramine, clomipramine, amitriptyline, nortriptyline, protriptyline, amoxapine, fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram, trazodone, nefazodone, venlafaxine, milnacipran, duloxetine, desvenlafaxine, vilazodone, vortioxetine, (levomilnacipran, chlorphentermine) | Antidepressants (unclassified) |
| OVOC3747 | Ion transport protein | Dronedarone, (nimodipine, felodipine) | Antiarrhythmics, class I and III (selective calcium channel blockers with mainly vascular effects) |
| OVOC1986 | KQT-1 potassium channel | Dronedarone | Antiarrhythmics, class I and III |
| OVOC1111 | Receptor family ligand binding region | Baclofen, oxybate | Muscle relaxants, central acting agents, null |
| OVOC5191 | G-protein coupled GABA receptor activity | ||
| OVOC12632 | NADH-ubiquinone oxidoreductase chains 1, 4 and 5; probable NADH dehydrogenase [ubiquinone] iron-sulfur protein 7 | Metformin | Blood glucose lowering drugs excluding insulin |
| OVOC6309 | 3-oxo-5-α-steroid 4-dehydrogenase | Dutasteride | Drugs used in benign prostatic hypertrophy |
| OVOC10592 | ERG2 and sigma1 receptor like protein | Pentazocine, (dextromethorphan) | Opiods, cough suppressants (other nervous system drugs) |
| OVOC8585 | C-terminal tandem repeated domain in type 4 procollagen | Xiaflex, (ocriplasmin) | Other drugs for disorders of the musculoskeletal system (other ophthalmologicals) |
| OVOC10695 | Glycosyl transferase family 21 | Miglustat, eliglustat | Other alimentary tract and metabolism products |
| OVOC4110 | Amidase | Acetaminophen | Other analgesics and antipyretics |
The table shows anatomical therapeutic classification groups for drugs identified as potential repurposing candidates. For drugs in parentheses, the mechanism is shown in similar style parentheses in the ‘ATC level 3 classification’ column.